BioSpace News Archive

Notable , which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that it is hosting a July 23 webinar titled, “Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes.” Speakers from the Stanford Cancer Institute and the MDS Foundation will explore current standards of care for MDS as well as emerging treatment options. The event will be mode

-Safety switches can be applied to CAR T, stem cell, and TCR Therapies - -Cells are created using a gene knockout, maintaining stability of the cells, avoiding additional genetic material and immunogenicity - -Manufacturing process enables 100% population of cells with a safety switch -

Hemogenyx Pharmaceuticals plc (LSE:HEMO)(“Hemogenyx Pharmaceuticals” or the “Company”), announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company (“Share Options”) to certain PDMRs and a member of the Scientific Advisory Board of the Company

uLab Systems, the creator of uDesign - the treatment planning software designed for orthodontists - is expanding its product offering to include aligner manufacturing

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 20,940,000 shares of common stock, par value $0.001 per share at an offering price of $0.50 per share, pursuant to a registered direct offering.

Esri, the global leader in location intelligence, today announced several new products and updates to the ArcGIS platform at the 40th Annual Esri User Conference (Esri UC).

Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that it has raised gross proceeds of approximately $90 million through its At-the-Market facility with participation based on interest received from RA Capital Management and Invus.

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the enrollment of adult patients for its Phase II trial for merimepodib, a broad-spectrum, orally administered antiviral drug candidate for the treatment of COVID-19, at four key trial sites.

ulrich medical USA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States announced the nationwide commercial release of the Momentum Posterior Spinal Fixation System.